Promising results were observed in a breast cancer trial (NCT02453620), where Entinostat was combined with Nivolumab (PD1 blocking antibody) and Ipilumab (CTLA-4 blocking antibody) [158]. This evidence concerns the gene PDCD1 and breast carcinoma.